Loxo Oncology, Inc. (NASDAQ: LOXO)is awaiting a Food and Drug Administration (FDA) decision on larotrectinib, a precision medicine for cancer in patients with NTRK gene fusions, but it's the company's LOXO-292 treatment for cancer in patients with RET fusions that could make it the MVP of the American Society of Clinical Oncology (ASCO) conference in 2018.
After the release of the ASCO presentation abstract in mid-May, Loxo's shares rocketed higher. Is this company's stock a buy?The Big Thing to Watch at ASCO 2018
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться